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The HIV epidemic is still a major concern. Virtually every country in the world has seen new infections in 1998, and the epidemic is out of control in many places according to the World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS). The introduction of highly active antiretroviral therapy (HAART), which has been used mainly in North America and Western Europe, has reduced the number of deaths caused by AIDS. However, because new infections continue to occur and infected people are kept alive with HAART and other combinations of anti-HIV drugs, the number of people living with HIV has increased in North America and Western Europe. Combinations of anti-HIV drugs often contain a non-nucleoside reverse transcriptase (RT) inhibitor (NNRTI), a nucleoside RT inhibitor (NRTI) and a protease inhibitor. This review will concentrate on the NNRTIs, of which the first, nevirapine (Viramune, Boehringer Ingelheim), was approved as a drug for the treatment of HIV-1 infection by the US Food and Drug Administration (FDA) in 1996. Nevirapine was followed by delavirdine mesylate (Rescriptor, Pharmacia & Upjohn) and efavirenz (Sustiva, DuPont), approved for the treatment of HIV-1 infection by the FDA in 1997 and 1998, respectively. A further three compounds, MKC-442 (Triangle Pharmaceuticals), Calanolide A (Sarawak MediChem Pharmaceuticals) and AG 1549 (Agouron Pharmaceuticals) are in clinical trials according to the Pharmaceutical Research and Manufacturers of America (PhRMA) 1998 survey report. Because of the increasing interest in NNRTIs we intend to review this class of compounds, especially the second generation of NNRTIs, using a chemical approach. This review will focus on the recent and most interesting published results. The NNRTIs synthesized before 1996 are covered by reviews by Artico (1996) and Tucker et al. (1996) . A review focusing on the role of NNRTIs in the therapy of HIV-1 infections has been published by De Clercq (1998a).
Non-nucleoside reverse transcriptase inhibitors
NNRTIs are bound in a hydrophobic pocket proximal to the catalytic site of RT in HIV-1 (Tantillo et al., 1994) . Xray crystallographic studies of NNRTIs in complex with RT (Ren et al., 1995; Ding et al., 1995) have shown that the NNRTIs maintain a very similar conformational 'butterflylike' shape and appear to function as π-electron donors to aromatic side-chain residues surrounding the binding pocket (Kroeger et al., 1995; De Clercq, 1998b) . The major problem in the development of new NNRTIs is the rapid emergence of resistant strains of HIV-1 in cell culture and patients. In patients receiving monotherapy with nevirapine, drug resistance developed rapidly owing to mutations in the RT; particularly significant is the Y181C mutation . Crossresistance is also a contributing factor and pyridinone-resistant strains containing the Y181C, K103N or both mutations have been found to confer resistance to both TIBO R82150 (Pauwels et al., 1990) and nevirapine (Merluzzi et al., 1990) . It has been shown that NNRTIs rapidly select for resistant mutant HIV-1 strains when selection pressure is applied by drugs in vitro (Kleim et al., 1995; Nunberg et al., 1991) or in monotherapy Miller et al., 1998) . Cross-resistance has been observed between many NNRTIs in development (Miller et al., 1998) . Mutations commonly selected for by NNRTIs occur at amino acid positions 98 to 108, 179 to 190 and 230 to 236 (Miller et al., 1998) . Cross-resistance is one of the obstacles that has to be overcome for the next generation of NNRTIs, new drugs that have a resistance profile that differs from the resistance profile of the already known drugs.
Many aspects beside selectivity and activity against mutant strains of HIV-1 have to be considered in the development of new NNRTI drug candidates. These aspects include metabolic stability, clearance rates, the ability to cross the blood-brain barrier and protein binding. Protein binding is a complex issue; a high protein binding could reduce the metabolism of the drug, the clearance rates and maintain high concentration of the drug in the blood. However, too strong protein binding may reduce the concentration of the free drug available for inhibitory action. Some of the currently most interesting subclasses of NNRTIs are described below. Tables showing the antiviral activity and activity against purified RT are presented. The presentation of each drug begins with the subclass with an FDA approved drug, followed by a subclass with a drug in clinical trials according to the PhRMA 1998 survey report, and ends with a description of some additional characteristic subclasses.
Nevirapine
Nevirapine (Viramune; Boehringer Ingelheim) ( Figure 1 ) was approved for the treatment of HIV in combination with nucleoside analogues in 1996 in the USA, and in 1998 in the European Union.
Nevirapine has a good potency against wild-type RT, with a 50% inhibitory concentration of 84 nM (Hargrave et al., 1991) , good metabolic stability, good bioavailability ) and crosses the blood-brain barrier eas- ily (Glynn & Yazdanian, 1998) . Like all current NNRTIs, nevirapine selects for mutations in the RT, the most common resistant strain of HIV-1 being characterized by the Y181C mutation. Mutations appear rapidly in response to treatment with NNRTIs administered as monotherapy, and the focus of researchers working with nevirapine analogues has been to develop drug candidates that retain activity against both wild-type HIV-1 and known NNRTI-resistant HIV-1 strains. The substitution pattern of the dipyridodiazepinone ring system in the search for new derivatives was changed from C-4 and N-11 to N-5 and N-11 , as this appears to be optimum for activity against both wild-type RT and Y181C RT (Proudfoot et al., 1995a) . Molecular modelling of the X-ray crystal structure of nevirapine bound to wildtype RT has revealed a lipophilic cavity proximal to the C-4 position, which allows for placement of an aryl group at this position. Although the placement of an amino group in the para position of this aryl group produced derivatives conferring activity against the Y181C mutant enzyme, the activity was not strong (Kelly et al., 1995) . Adding an aromatic substituent at position 2 afforded several analogues with activity against both wild-type RT and Y181C mutant RT (Proudfoot et al., 1995a) and some have also shown activity against the Y188L mutant RT (Kelly et al., 1997) (Table 1) . Changing the position of the aromatic substituent from position 2 to position 8, and introducing an ethyl linker, have afforded new analogues with anti-HIV activity against both wild-type RT and a broad spectrum of mutant RTs . The aim in the synthesis of these derivatives has been to achieve multiple interaction points with the enzyme or to achieve interaction between the compound and some more conserved residues of RT. Some of these residues include the catalytic aspartic acid residues, Asp-110, Asp-185 and Asp-186. Mutation of these residues results in inactive RT enzymes (Larder et al., 1987) . Further research has investigated the linker between the aryl substituent and the dipyridodiazepine system . The preferred substitution at the 8 position was with an aryloxymethyl or an arylthiomethyl, the arylthiomethyl derivatives being the most active compounds ( Table 2 ). The aryloxymethyl compounds though, were metabolically more stable, less toxic and yet possessed good activity, and are thus the choice for further development rather than the thio analogues .
Several derivatives of nevirapine with changes in the ring system have been synthesized and tested. Some of these are the dipyrido[2,3-b:2′,3′-c]diazepinones (Proudfoot et al., 1995b) , pyridazinobenzodiazepines (Heinisch et al., 1997a; Barth et al., 1996) and pyridobenzodiazepines (Hargrave et al., 1991) . However, none of these have shown an improved anti-HIV potency.
Dibenzoxapinones and pyridobenzoxazepinones (Tables  3 and 4 ) are analogues of nevirapine that have shown activity against HIV-1 RT in the nanomolar range (Klunder et al., 1992). As a class, oxazepinones are less potent HIV-RT inhibitors than the diazepinones. This problem has been partly solved by substituent optimization. However, solubility is a problem for this class of compounds because oxazepinones have the disadvantage of being less soluble than diazepinones. Replacing a phenyl ring with a pyrimidine ring in the dibenzoxazepinones may increase the solubility, but is often accompanied by a decrease in the inhibitory effect on RT (Klunder et al., 1992) .
BHAP
Bis(heteroaryl)piperazine (BHAP) RT inhibitors form a class of compounds, discovered by the Upjohn laboratories (delavirdine, atevirdine; Pharmacia & Upjohn) (Romero et al., 1991) . This subclass of NNRTIs contain delavirdine mesylate (rescriptor), which was given FDA approval in April 1997 for therapeutic use against HIV-1. Atevirdine mesylate is another compound of this class that was chosen for clinical evaluation (Romero et al., 1994) . The structures of delavirdine mesylate (U90152S) and atevirdine mesylate (U87201E) are shown in Figure 2 . Later work has led to new analogues, the (alkylamino)piperidine BHAPs (AAP-BHAP). This has produced compounds with activity against RT containing the Y181C and P236L mutations. The proline to leucine mutation at position 236 appears in RT after several HIV-1 passages in vitro in the presence of increased concentrations of atevirdine or delavirdine . Some AAP-BHAPs have, in a structure-activity relationship programme, demonstrated excellent activity against the wild-type virus (Table 5) .
Delavirdine has been found to block the replication of 25 Klunder et al. (1992) . Klunder et al. (1992) . primary HIV-1 isolates in peripheral blood lymphocytes (PBL), including variants that are highly resistant to 3′-azido-3′-deoxythymidine (zidovudine) and 2′,3′-dideoxyinosine (didanosine), with a mean 50% effective dose (ED 50 ) of 0.066±0.137 µM (Dueweke et al., 1993) . The mutations Y181C and K103N conferred some resistance to delavirdine, as for many other NNRTIs. However, delavirdine has been shown to inhibit the Y181C mutant RT with the rA.dT template:primer at a 50% inhibitory concentration (IC 50 ) of 8.3 µM, whereas nevirapine and L-697,661 failed to achieve 50% inhibition at 60 µM. This, together with good oral bioavailability and good serum drug levels in animals, made the mesylate salt of delavirdine a candidate for clinical trials (Dueweke et al., 1993) . These compounds did not, however, possess the desired pharmacokinetic profile, primarily due to high clearance rates. This afforded a new structure-activity relationship programme focusing on compounds with increased activity against mutant RT (P236L and Y181C) with the appropriate pharmaceutical properties. These included alteration of the 3-pyridine substituent because N-dealkylation of the pyridine 3-alkylamino substituent is a predominant pathway for metabolism of the BHAPs . Work included varying the lipophilicity and introducing polar water solubilizing groups. Because delavirdine also underwent hydroxylation at C-6 of the pyridine ring, this position was targeted for blocking. This was done by synthesizing compounds containing a halogen at C-6 and one compound containing a pyridazine ring where nitrogen replaced C-6 . Substituting an ethyl for a methyl group on the aminopiperidine spacer enhanced the activity against Y181C and P236L mutant RTs . Some of the most active compounds in this series are presented in Table 6 .
Replacing the 3-alkylamino in both BHAPs and AAPBHAPs with alkoxy groups has also been investigated (Genin et al., 1996) . Incorporation of a 3-alkoxy substituent has been shown to be beneficial on the metabolic stability, evaluated in the presence of hepatic microsomal cytochrome P450 in vitro, thus providing analogues with similar or greater metabolic stability than delavirdine. Some of these compounds possessed good activity against wild-type and P236L RT enzymes, but the activity against Y181C RT was diminished (Genin et al., 1996) .
Benzoxazinones
Benzoxazinones are the third class of compounds from which a non-nucleoside inhibitor has been approved by the FDA. Efavirenz (DMP-266; DuPont) ( Table 7) was approved in September 1998 by the FDA for once-daily dosing to be used in combination with other anti-HIV drugs in both adult and paediatric patients.
Efavirenz is a very potent inhibitor against a wide range of mutant HIV-1 RTs. Its activity against some of these are presented in Table 8 . In cell culture efavirenz selects for a double mutation (L100I plus L103A) following 10 serial passages at increasing concentrations (Young et al., 1995a) . However, no single RT substitution has yielded a mutant Romero et al. (1996) . (Table 8 ). The lowest concentration of efavirenz that has yielded evidence of cytotoxicity, both in primary cells and in T cells, is 80 µM, giving a selectivity index of approximately 80000 (Young et al., 1995a) .
HEPT derivatives
1-[(2-Hydroxyethoxy)methyl]-6-(phenylthio)thymine, HEPT (Figure 3 ), is the lead compound of this class of NNRTI and was described in 1989 (Miyasaka et al., 1989) . HEPT was synthesized as an acyclonucleoside and was expected to be a member of the nucleoside class of RT inhibitors, which act as competitive inhibitors by mimicking the natural substrate for the enzyme (Tantillo et al., Romero et al. (1996) . 1994). However, in antiviral testing it was found only to inhibit HIV-1 and not HIV-2. From this it was deduced that HEPT was different in its mechanism of inhibition of HIV than the known nucleoside inhibitors zidovudine, stavudine and didanosine.
Studies of the structure-activity relationship of HEPT analogues have led to the synthesis of MKC-442 (I-EBU; Triangle Pharmaceuticals) (Figure 3 ), which has entered Phase III clinical trials. The importance of the substitution pattern of the thiophenyl ring in the 6 position and the substituent at the 5 position were among the first characteristics to be studied (Tanaka et al., 1992a) . Substituting the methyl group in the 5 position of HEPT with ethyl or isopropyl gave a marked increase in potency (Tanaka et al., 1992a) , whereas substitution with a hydrogen atom resulted in loss of activity. Also, the substitution pattern of the 6- Young et al. (1995a) . Young et al. (1995b) .
(phenylthio) moiety was investigated and substitution at the 2 or 4 position was ineffective, whereas substitution at the 3 position with methyl, ethyl or a fluoro substituent increased the potency. Introduction of a methyl group or a chlorine at both the 3 and 5 position was even more effective (Tanaka et al., 1992a) . Removal of the hydroxyl group in the (2-hydroxyethoxy)methyl side chain also improved the potency (Tanaka et al., 1992b) . Changing the phenylthio moiety with benzyl analogues yielded even more potent inhibitors of HIV-1 with selectivity indices of up to 130000 (Tanaka et al., 1995) . After studies on pharmacokinetics and following toxicology tests, MKC-442 was selected as the candidate for clinical trials for AIDS chemotherapy (Tanaka et al., 1995) . The oral bioavailability of MKC-442 in rats was 18.4% and the 50% lethal dose in rats was >2000 mg/kg (Tanaka et al., 1995) . After molecular modelling studies on HEPT derivatives (Hopkins et al., 1996) , an analogue of MKC-442 with naphtyl in place of phenyl was synthesized, but it was 10-fold less active than MKC-442 and more toxic (Danel et al., 1997) . Many derivatives with variations in the N-1 substituent have been synthesized. Among these are some with more bulky groups, such as E-BPU (Tanaka et al., 1991) (Table 9) . Some have amines, amides and alkene functionalities that are introduced into the N-1 linker between the pyrimidyl moiety and different aromatic rings, for example, phenyl, 2-furyl, 2-thienyl, 2-benzofuranyl and so on (Pontikis et al., 1997) . Some 1-substituted (ethylthio)methyl and (methylthio)methyl analogues have shown anti-HIV-1 activity comparable to MKC-442 and although they have higher cytotoxicity, they still have high selectivity indices (6200 to 17000) (Danel et al., 1996) . Derivatives with a selenyl in place of sulphur in the (phenylthio) moiety have also been prepared (Kim et al., 1996) and some with activities and selectivities that are comparable to those obtained for MKC-442. Some HEPT derivatives are highly bound to human serum proteins and have been tested for antiviral activity in the presence of varying percentages of human serum (HS) in place of foetal bovine serum (FBS) (Baba et al., 1993) . MKC-442 (I-EBU) showed EC 50 values of 0.014 µM (in 10% FBS), 0.018 µM (in 10% HS), 0.026 µM (in 30% HS) and 0.063 µM (in 50% HS). Some 2-thio analogues of HEPT have also been prepared and although the anti-HIV activity has been good, they all bound with high affinity to HS proteins, some with only 0.3 to 0.7% of the total compound remaining unbound to proteins (Baba et al., 1993) . (1996) . EC 50 was determined by the p24 antigen method and the MTT method was used for CC 50 . The values are expressed as the mean of three independent determinations; ¶Kim et al. (1996) . The values were determined in CEM-SS cells and are the mean of two independent determinations in duplicate.
Dihydroalkoxybenzyloxopyrimidines and thio analogues
The dihydroalkoxybenzyloxopyrimidines (DABOs) and their thio analogues (S-DABOs) are closely related to the HEPT derivatives. DABO derivatives are characterized by an alkoxy substituent, the S-DABOs by a thioalkyl group, at C-2 in place of the N-1 substituent in the HEPT derivatives ( Figure 4 ). Some 6-benzylpyrimidines were synthesized as dihydrofolate reductase inhibitors and because of their structural similarities with HEPT they were tested, and some were found to be active, against HIV-1 (Botta et al., 1992) . Unlike the HEPT derivatives, the DABOs are active with hydrogen in the 5 position comparable with compounds having a methyl group in the 5 position (Artico et al., 1993) . Substituting the 5 position with an ethyl or isopropyl does not increase the anti-HIV activity, however the size of the C-2 alkoxy group seems to be important. The best activities are achieved with bulky substituents for R 2 (Figure 4) , such as cyclohexyl, cyclopentyl or sec-butyl (Artico et al., 1993) . A methyl substituent in the 3′ position increases the activity, whereas an additional methyl substituent in the 5′ position does not always increase the potency. A compound with methyl in the 5 position, 3′,5′-dimethyl substituted in the phenyl moiety and a sec-butyl in the alkoxy group at C-2 had a selectivity of >416, and has been one of the most active among the first DABO compounds .
Replacing the side chain oxygen in the 2 position with sulphur led to the S-DABO compounds, which showed increased anti-HIV-1 activity . Alkylation at N-3 and replacing C=O with C=S in the 4 position of the pyrimidine ring led to compounds devoid of activity, whereas substituting the 6-benzyl group with 1-naphtylmethyl enhanced the activity of the S-DABO compounds (Mai et al., 1997) . Some highly active anti-HIV-1 compounds with a (methylthiomethyl)thio substituent at C-2 of the pyrimidine ring (Table 10 ) have been designed based on the structure of the NNRTI binding pocket of RT . Molecular modelling supporting a hypothesis of beneficial π-stacking interaction between Tyr-188 of the NNRTI binding pocket in RT and the DABOs with 2,6-dihalogenation in the benzyl group, has led to highly potent inhibitors of HIV-1 (Mai et al., 1999) . Some activities of S-DABO compounds are presented in Table 10 .
Bicyclic derivatives that can be considered as hybrids between S-DABOs and HEPT analogues have also been synthesized (Danel et al., 1998) (Figure 5 ).
These compounds showed only moderate anti-HIV activity with the lowest EC 50 value of 0.7 µM for the compound with R 1 =ethyl, R 2 =3,5-Me 2 C 6 H 3 CH 2 and R 3 =ethyl. Some analogues with the thiazole ring fused to the C-2 and N-3 bond of the S-DABO pyrimidine ring was also synthesized, but these were either too toxic to the host cells or devoid of antiviral activity (Danel et al., 1998) .
Imidazoles
In a screening programme seeking NNRTIs that would inhibit HIV-1 strains that are resistant to known NNRTIs or to zidovudine, AG 1549 (formerly S1153; Agouron Pharmaceuticals and Shionogi Research Laboratories) was selected from a set of derivatives of an initial lead compound (Fujiwara et al., 1998) . AG 1549 is a highly substituted imidazole ( Figure 6 ), and had an IC 50 value of 0.45 µM in a standard RT assay with poly(rA) and oligo(dT).
Some of the beneficial characteristics for AG 1549 are a higher concentration in lymph nodes than in plasma after oral administration to rats and an in vitro selectivity index of 8000 (Fujiwara et al., 1998) . The activities of AG 1549, nevirapine, delavirdine and loviride were compared against HIV-1 mutant clones (Table 11) .
Mutant clones with single amino acid substitutions at residues 100, 103, 106, 181, 188, 190, 227 and 236 showed less than 10-fold reduced sensitivities compared to the wild-type strain, whereas the clone with mutation L234I was 22-fold less sensitive to AG 1549 (Fujiwara et al., 1998) and was more sensitive to nevirapine and loviride than the wild-type HIV strain. The double mutant strain with the V106A plus Y181C mutation was still sensitive to AG 1549, whereas the double mutant strain V106A plus F227L was only somewhat sensitive.
AG 1549 was tested for in vitro selection of mutant strains of HIV-1 and two clones were found and sequenced. In both case more than one amino acid substitution mutation was present. One strain contained the mutations V106A plus F227L and the EC 50 value for the clone was 740 ng/ml (1.6 µM). Another clone containing K103T, V106A plus L234I had an EC 50 value of 37 ng/ml (0.08 µM) in cell culture using the MTT assay (Fujiwara et al., 1998) .
Many NNRTIs bind to serum proteins, and AG 1549 has the greatest affinity for human albumin. In the presence of 50 mg/ml of HS albumin and 1 mg/ml alpha-1-acid glycoprotein, AG 1549 showed a ninefold reduction in its activity compared with the activity without albumin. Taking this into account, AG 1549 may still have a sixfold greater antiviral activity than nevirapine in human plasma (Fujiwara et al., 1998) . AG 1549 is now undergoing clinical testing.
TIBO
Since the TIBO class ( Janssen Research Foundation) was introduced as non-nucleoside inhibitors of HIV in vitro (Pauwels et al., 1990) , a lot of work concerning structure-activity relationships has been done using this class of compounds (Figure 7) .
In the early work of optimizing the TIBO class, it was found that a 3-methyl-2-butenyl substituent on N-6 (Kukla et al., 1991a) , a methyl substituent at position 5 and a thione in position 2, gave a very potent inhibitor of HIV-1, particularly if the 5 position had the S-configuration (R82150) (Pauwels et al., 1990) (Figure 8 ). Additionally, a chloro substituent in position 9 gave a compound (R82913) that had a 10-fold increase in activity, but also an increase in cytotoxicity (Pauwels et al., 1990) . Changing the chloro substituent from position 9 to position 8 afforded a compound (R86183) even more potent . Compound R82913 has been subject to clinical Phase I testing.
In the imidazole part of the structure it has been found that replacement of the carbonyl oxygen with sulphur or selenium causes an increase in the activity. A number of variations in this position have been tested, including Sphenylthiourea and O-methylated urea, and all have been inactive. The proton on nitrogen in position 1 appeared to be necessary, especially for the urea compounds, and this group may be involved in direct hydrogen bonding to the enzyme. Replacing the nitrogen in position 3 with a carbon resulted in loss of activity. Most changes in the imidazole structure resulted in less active compounds or a total loss of activity (Kukla et al., 1991b) .
Substitutions on the diazepine ring have also been investigated . The 5-mono-methyl-substituted analogues, which were the original substitutions in the early lead compounds, and 7-mono-methyl-substituted analogues were comparable, being the most active in the series. The 4,5,7-unsubstituted analogue and the 4-monomethyl-substituted analogues were less active. Substituting larger and more bulky groups such as isopropyl and phenyl Fujiwara et al. (1998) . produced no advantage except for compounds substituted with isopropyl in position 4 and with an oxo group in position 2, which were more active than the 4-methyl analogues. Some (4 plus 5, 4 plus 7, 5 plus 6, 5 plus 7, 6 plus 7 and 7 plus 8) disubstituted or ring fused analogues were also prepared . The 5,7-di-Me (trans) analogue was slightly better than the 5-mono substituted analogue, being the most promising with an EC 50 value of 0.042 µM in MT-4 cells. From this, the R,R (trans) and S,S (trans) 5,7-dimethyl analogues were prepared for the 2-oxo and 2-thio analogues. These compounds have a different structure-activity relationship to the 5-methyl analogues. The 2-oxo compounds were slightly more active than the thio analogues and a chloro substituent at the 9 position resulted in a significant loss in activity. Substitution in the aromatic part of the TIBO structure has also been investigated . Substituents in the 8 position gave a large improvement in activity compared with the parent compound, whereas substituents at the 9 position tended to have little effect on activity and 10 substituents decreased the activity (Table 12 ).
PETT
The phenethylthiazolylthiourea (PETT) compounds were derived from a systematic disassemblage of the molecular structure of the known TIBO HIV-1 RT inhibitors (Ahgren et al., 1995; Cantrell et al., 1996) . The lead compound of this series was LY73497 (Figure 9 ). Optimization of this lead gave N-[2-(2-pyridyl)ethyl]-N-[2-(5-bromopyridyl)]thiourea hydrochloride (LY300046:HCl) (trovirdine; Medivir), which has been selected for clinical trials.
Extensive structure-activity relationship studies of the PETT compounds have been made. For this purpose the structure of PETT is considered as a product of four parts (Figure 10 ).
In part 1 of the structure, the phenethyl moiety, the substitution patterns have been investigated. Meta and particularly ortho substitution is preferred over para substitution (Bell et al., 1995) . Both mono substitution , di and tri substitution (Bell et al., 1995) have given very active compounds. The characteristics of the substituents have also been investigated (Bell et al., 1995) . Both electron donating and electron withdrawing of small groups like fluoro, chloro, azido and methoxy substituents were comparable with good activity. The chain length of an alkoxy substituent was investigated, and the ethoxy substituent gave the maximum activity, whereas the more sterically demanding propoxy and isopropoxy substituents decreased the activity. Compounds where the phenyl group was replaced with 2-pyridyl, as in trovirdine, gave the most active compounds in a series with different heterocycles. Active compounds have also been prepared with saturated Pauwels et al. (1990) . ¶Data from Kukla et al. (1991b) . **ND, not determined. † †Data from Ho et al. (1995) . ‡ ‡Data from Pauwels et al. (1994) .
heterocycles such as 1-piperidinyl and 1-piperazinyl .
In part 2 of the molecule the ethyl linker was optimal for activity. Methyl substitution in the benzylic position enhanced activity, whereas a methyl in the phenylethyl position diminished activity (Bell et al., 1995) . A cyclopropyl linker with cis configuration, has been shown to be an advantage for the urea-PETT analogues (Sahlberg et al., 1998) .
For part 3 of the molecule the N,N-unsubstitutedthiourea was most active (Bell et al., 1995) . Methyl substitution on nitrogen adjacent to the phenethyl side chain completely eliminated activity, whereas methyl substitution on the nitrogen adjacent to the thiazole ring only decreased the activity slightly. The reason for the difference in activity for N-methyl substitution may be owing to an internal hydrogen bond (Figure 11 ).
Compounds with a urea part in place of the thiourea have also been prepared. They give lower activity but may possess better pharmacological properties than the thiourea compounds (Sahlberg et al., 1998) .
In part 4, the thiazole moiety, the most optimum compounds have been achieved by replacing the thiazole with a 5-bromopyrid-2-yl. In the thiazole series several 4-substituted derivatives, including small alkyl, cyano, trifluoromethyl and ethoxycarbonyl substituted compounds were quite potent inhibitors (Bell et al., 1995) . In a series where the thiazole was replaced with diazinyl it seemed that the nitrogen in the 2 position was essential because the 4-pyridazinyl derivate was devoid of activity (Heinisch et al., 1997b) . This seems to be in accordance with the proposed internal hydrogen bond in anti-HIV active PETT compounds ( Figure 11 ).
The activity of new NNRTIs against strains of HIV resistant to known NNRTIs is becoming more important, and the PETT compounds show good activity against some of the known resistant strains of HIV. Some of the PETT derivatives showing good activity against single mutations (Ile-100 and Cys-181) were tested in assays against two double mutant HIV-1 strains. Five of the tested compounds showed ED 50 values below 10 µM against one of the two double mutants (Ile-100 plus Asn-103 or Ile-100 plus Cys-181) (Cantrell et al., 1996) . These five compounds are listed in Table 13 .
The PETT compound trovirdine has shown to readily penetrate the blood-brain barrier, as the concentration in brain tissue parallelled those in plasma of male Fischer 344 rats (Ahgren et al., 1995) . The in vitro protein binding of trovirdine was 88.7% in rat plasma and 95.5% in human Trovirdine has an ED 50 in HIV-1-infected MT-4 cells of 0.020 µM, and an IC 50 value against wild-type HIV-1 RT of 0.015 µM and IC 50 values against mutant HIV-1 RTs of 0.43 µM (Ile-100) and 2.50 µM (Cys-181) (Cantrell et al., 1996) . plasma at a concentration of 2 µg/ml. Because of its simple chemical synthesis, excellent antiviral activity, satisfactory pharmacokinetic profile and acceptable toxicity, trovirdine entered Phase I clinical trials (Ahgren et al., 1995) , but was later withdrawn.
Urea-PETT
The urea-PETT compounds may have better toxicological and phamacokinetic properties than the PETT compounds. It was found that the urea-PETT compounds maintain their antiviral activity in cell culture in the presence of added HS much better than the thiourea compounds (Sahlberg et al., 1998) . This point urged the researchers at Medivir AB to make a structure-activity research (SAR) programme in which different urea-PETT analogues were synthesized and evaluated (Table 14) . This gave ethyl linked (1-6) and conformational restricted cyclopropyl analogues (7-13). The cyclopropyl compounds were in general more potent than the ethyl linked compounds, especially against mutant HIV strains.
Alkenyldiarylmethanes
Alkenyldiarylmethanes (ADAMs) were introduced as a new class of NNRTIs in 1995 (Cushman et al., 1995 (Cushman et al., , 1996 . This afforded the first lead compound 3′,3′′-dibromo-4′,4′′-dimethoxy-5′,5′′-bis(methoxycarbonyl)-1,1-diphenyl-1-heptene, with an EC 50 value of 9.2 µM and a selectivity index of 15. Further work has lead to methyl 3′,3′′-dichloro-4′,4′′-dimethoxy-5′,5′′-bis(methoxycarbonyl)-6,6-diphenylhexenoate (ADAM II) as the currently most potent compound of this class, with an EC 50 value of 13 nM and a selectivity index of 2430 (Cushman et al., 1998a,b) . Bromo-and chloro substituents are preferred over iodoand unsubstituted derivatives (Table 15 ). The length of the alkenyl substituent is also important and it appears that a six atom chain is optimal for anti-HIV-1 activity (Cushman et al., 1998a) .
Pyrimidine thioethers
Pyrimidine thioethers (Pharmacia & Upjohn) as inhibitors of HIV-1 RT were first reported by Althaus et al. (1996) . This class of RT inhibitors is primarily characterised by its potent activity against the P236L mutant, which renders HIV-1 resistant to delavirdine (Nugent et al., 1998) . The lead compound of this class was 6-chloro-2-benzylthio-4-pyrimidinamine, and several derivatives were investigated by Nugent et al. (1998) . Exchange of the chloro moiety in the pyrimidine ring with trifluoromethyl gave a compound only a little less potent, whereas exchange with other electron-withdrawing groups was not so good. In the place of R (Table 16 ) the enzyme can accommodate a large, but flat, hydrophobic group. This could be an aryl group or an alkenyl group. A secondary amide attached to an alkenyl has significantly less activity compared to a tertiary amide. This is thought to be caused by a hydrogen bonding proton, or for steric reasons, in the lipophilic pocket of the enzyme. Substitution of the sulphur with oxygen or nitrogen decreased or removed the activity. Oxidation of the sul- Nugent et al. (1998) . phur diminished the activity, and removal of the methylene linker resulted in compounds devoid of activity. Table 16 shows some of the compounds with activity against wildtype and the delavirdine-resistant HIV-1 (P236L) mutant (Nugent et al., 1998) . Further study within the pyrimidine thioethers for compounds with broad activity against several NNRTI-resistant variants of HIV-1 have led to the furo[2,3-c]pyridinethiopyrimidine class of compounds. These are characterized by the aralkyl group and a methyl substituent at the methylene linker. This methyl substitution introduces a stereocentre at the carbon in the methylene linker (Table  17) Wishka et al. (1998a) . Arranz et al. (1998) . extremely potent inhibitors of wild-type HIV-1 RT with IC 50 values (rA.dT) from 20 to 85 nM, and of the mutant RT P236L that is resistant to delavirdine, with IC 50 values from 22 to 25 nM (Wishka et al., 1998a) . Interestingly, activity against Y181C RT, which is observed to occur when HIV-1 cultures are under pressure from many known NNRTIs, was found to be dependent on the stereochemistry of these thiopyrimidines. PNU-142721, the (S)-enantiomer, and the racemate were found to inhibit the enzyme with IC 50 values in the submicromolar range, whereas the (R)-enantiomer was inactive. In cell culture PNU-142721 was very potent against HIV-1 wild-type and several strains of HIV-1 resistant to known NNRTIs (Table 17) .
Another compound in this series, PNU-109886, with a methyl substituent in the furo[2,3-c]pyridine moiety has displayed increased potency against virus containing the Y181C mutation. However, it is characterized by a less favourable pharmacokinetic profile than PNU-142721 (Wishka et al., 1998b) . PNU-142721 possess high antiviral activity against a broad spectrum of HIV-1 variants and a favourable pharmacokinetic profile, including penetration of the blood-brain barrier in the rat. The levels of PNU-142721 found in the brain in an experiment with rats was 75% of the simultaneous plasma concentrations (Wishka et al., 1998a) . (Witvrouw et al., 1998) . The basic requirements for the structure of TTDs is N-4 alkyl and N-2 benzyl groups (Table 18) . Two compounds with a 2-picolyl in place of the N-2 benzyl were less active, whereas a 3-picolyl derivative and a 2-picolyl derivative with a benzyl group at N-4 was more potent than the benzyl analogues . Halogens have been substituted at the N-2 benzyl moiety, with optimum results achieved by one ortho-or metha substituent because a 3-fluorobenzyl derivative was more potent than the 3,5-difluorobenzyl analogue (Witvrouw et al., 1998) . The best results concerning the N-4 alkyl substituent have so far been with cyanomethyl, propargyl and benzyl. Substituents of methyl, ethyl, propyl, allyl and cyanoethyl at N-4 produce less active compounds Witvrouw et al., 1998) . Other bicyclic systems, where changes in the thiophene ring of the thieno[3,4-e][1,2,4]thiadiazine have been tried, resulted in less active compounds. Systems that have been investigated are thieno[2,3-e], 6-methylpyrazolo[3,4-e] and 6-chlorothieno[3,2-e] fused TTD analogues (Figure 12 ).
Carboxanilides and thiocarboxanilides
Oxathiin carboxanilide, UC 84 (NSC 615985), was originally synthesized as a potential fungicide by chemists at the Uniroyal Chemical Company. In a screening programme by the National Cancer Institute, UC 84 exhibited anti-HIV activity. UC 84 completely protected CEM-SS cells infected with HIV-1 from the cytopathic effect of HIV with an EC 50 value ranging from 0.1 µM to 1.0 µM, depending on the infectivity condition (Bader et al., 1991) . UC 84 served as a lead (Balzarini et al., 1995) and consists of an oxathiin moiety (part a), a carboxamide group (part b) and a 2-chlorobenzoic acid (part c) that is esterified with an isopropyl group (part d) (Figure 13) .
A series of derivatives was synthesized (Balzarini et al., 1995) with the following changes: part a, the oxathiin part, Balzarini et al. (1995) . was replaced by various alkoxy groups; part b was modified from C=O to C=S, which in most cases increased the activity; part c was mostly unmodified; and part d was modified with a variety of substituents. The eight most interesting compounds in this series, UC 38 being the most potent, are presented in Figure 14 , and test results against HIV wildtype and four mutant strains are presented in Table 19 .
Further work with the thio analogues of this series have led to three new highly active compounds related to UC 10 ( Figure 15 and Table 20) , with the compound UC 781 as a very potent inhibitor .
UC 781 shows excellent inhibitory activity against several mutant HIV-1 strains, including the L100I, V106A, E138K and Y181C mutations (Table 21 ). In a test it has selected for the mutations Y181C, V108I and K101E in order of appearance . UC 781 was shown to be a rapid tight-binding inhibitor of HIV-1 RT . In addition, UC 781 has been found to readily penetrate isolated HIV-1 particles, and treatment of isolated HIV-1 virions with UC 781 result in rapid inactivation of the virus . UC 781 may thus be very interesting in a more protective manner as an agent in retrovirucidal formulations.
TDA (thiadiazole derivatives)
The basic structure of the TDA derivatives is presented in Table 22 . A derivative (RD3-2356) with a 2-chloro substituent in the phenyl moiety enhanced the activity compared with a derivative containing an unsubstituted phenyl moiety (RD3-2105) (Hanasaki et al., 1995) . A 4-chloro substituent has the opposite effect, producing compounds with decreased or lacking activity (Ijichi et al., 1996) . Investigating the R2 and R3 alkyl substituents revealed that the most potent congener of the TDA derivatives is 4-(2,6-dichlorophenyl) -1,2,5-thiadiazol-3-yl N-methyl-Npropylcarbamate (RD4-2024) , whereas the monoalkylcarbamate derivative, RD3-2380, was without inhibitory effect (Ijichi et al., 1996) . The easy synthesis of TDA derivatives made them potential drug candidates for HIV-1 infection (Hanasaki et al., 1995) .
Sequence analysis of mutants resistant to TDA derivatives has revealed a point mutation at position 181 (Tyr→ Cys) (Ijichi et al., 1996) . When anti-HIV-1 assays were carried out in the presence of 50% HS to evaluate TDA under more physiological conditions, the inhibitory effects on HIV-1 replication showed a 10-200-fold decrease. The degree of reduction depends on the lipophility, more lipophilic leading to less inhibitory effect. The TDA derivatives were bound to serum protein by more than 90% under these conditions (Ijichi et al., 1996) .
Diarylsulphones
The basic structure of diarylsulphones consists of two substituted phenyl groups linked by a sulphone group. In a screening of 54 diarylsulphones and related derivatives, 2- Buckheit et al. (1997) . †50% cytotoxic concentration. ‡Therapeutic index. Data from Buckheit et al. (1997) . Buckheit et al. (1997) .
nitrophenyl phenyl sulphone (NPPS) was identified as a RT inhibitor of the non-nucleoside class (McMahon et al., 1993) . The most active compounds are those with an ortho-nitro group (McMahon et al., 1993; Buckheit et al., 1996) . Several of the most active compounds in a series studied by Buckheit et al. (1996) had a chloro and a methylamine on the ring not containing the nitro group (Table  23) et al., (1996) . slightly less active (Buckheit et al., 1996) and reduction of the sulphone linker also reduces the antiviral activity (McMahon et al., 1993) . Compound NSC 667952 was the most active in the series, retaining activity against the drugresistant virus isolate and having a sensitivity profile against the L100I mutation (Buckheit et al., 1996) . The diarylsulphones have recently been investigated as HIV-1 integrase inhibitors. Some have been found to be interesting enough for further investigation (Neamati et al., 1997) .
Calanolide A et al., 1992) . From this extract some coumarins were isolated and identified. The most active of these compounds, in descending order, were (+)calanolide A, (+)calanolide B and the ester derivative 12-acetoxycalanolide (Sarawak MediChem Pharmaceuticals) ( Figure  16 ). In a search for calanolide A in other and more abundant sources, several species of callophyllum were tested (Fuller et al., 1994) . In the latex from C. teysmannii miq. var. inophylloide, a compound identified as the (-)calanolide B or costatolide was isolated and tested. This costatolide, though a known compound not previously identified as having antiviral activity, showed anti-HIV activity compa- Buckheit et al. (1996) . *Assays using MT-4 cell culture preinfected with HIV-1 IIIB at a low multiplicity. †Concentration that caused 50% inhibition of HIV RT. ‡Concentration that inhibited the spread of HIV-1 infection by ≥95%. Data from Goldman et al. (1991) .
rable to (+)calanolide A (Fuller et al., 1994) . A lot of structure-activity studies concerning (+)calanolide A and (-)calanolide B have been performed (Galinis et al., 1996; Zembower et al., 1997) and despite increased knowledge of the structure-activity relationship for this class of NNRTI, no new compounds more potent than the lead compounds have been found. Calanolide A is presently in clinical testing.
Pyridinones
The pyridinones L-697,639 and L-697,661 (Merck Research Laboratories; Figure 17 ) were reported in 1991 . Compound L-697,661, with 95% clearance concentration (ClC 95 ) values in the nanomolar range, has been clinically tested and good antiviral activity was observed. However, antiviral activity was of short duration owing to rapid onset of viral resistance . When new drug candidates are tested in HIV antiviral and RT enzymatic assays they are often compared to L-697,661.
Structural modifications on the 2-pyridone moiety have not been successful Saari et al., 1992) . These include N-methylation, O-methylation, deletion of one or both alkyl groups and substituting 5-ethyl with 5-methyl. Some structure-activity studies have also been done replacing the benzoxazole by a pyridyl or a phenyl (Table 24 ). It was found that maximum enzyme inhibition was obtained with compounds containing a 2′-methoxy group on either the phenyl or pyridyl ring. In the phenyl subclass several substituents were tried in the ortho position. Ethoxy-and nitro substituents were comparable with the methoxy substituent and some substituents (CN, F, Cl, MeS, Me) gave only modestly active compounds. Substituents such as CF 3 , NH 2 and MeOCH 2 were detrimental to activity. There is no significant difference between the 2-methoxyphenyl and 2-methoxy-3-pyridyl derivatives. In the pyridyl subclass the position of the pyridine nitrogen was found to be important, with the position of nitrogen at 3′ as the most Hoffman et al. (1993) . Table 24 ) was selected for clinical evaluation due to the best oral availability in rats and monkeys.
A structure-activity relationship study of 2-pyridinones with a hydrolytically more stable ethyl linker in place of the amino-methylene linker was made although the original lead had shown less potential with an ethyl linker. As observed in earlier studies, a change in the length or a reduction in the flexibility decreased the inhibitory potency. The effect of thiocarbonyl modification of the pyridinones was minimal in enzyme inhibition, but they were less effective in the prevention of virus spread in cell culture, which could reflect poorer cell penetration of these pyridinethione analogues. Many of the compounds with a benzoxazole as in L-697,661 and an ethylene linker were highly active, particularly those unsubstituted, substituted in the 4 or 7 position or disubstituted in the 4 and 7 position. The number of potent candidates was reduced by investigating the susceptibility of hydrolysis in acidic environments. This revealed one compound, the unsubstituted analogue 1 in Table 25 , 10-fold more stable to acid hydrolysis than the other derivatives. Compounds with an ether, or a thioether linker were also prepared and tested (Table  25 ). The ether linker decreased the activity, whereas the analogue of L-697,661 with a thioether linker was more inhibitory to HIV-1 RT than L-697,661 and had an improved stability in an acid environment. It was not as stable as the unsubstituted counterpart with an ethyl linker (Compound 1 in Table 25 ).
The early candidate of the pyridinones, L-697,661, was very tightly bound (99.6%) to human plasma and compound 1 was found to be 4% unbound to human plasma protein, which suggested a 10-fold higher free drug level in vivo. Compound 1 has been studied clinically in HIV-positive patients. Resistance to compound 1 has been observed in cell culture experiments with virus from clinical isolates obtained from patients who developed resistance to L-697,661 .
α-APA (α-anilinophenylacetamide)
A screening programme of 2000 compounds belonging to different classes led to the discovery of the lead α-APA derivative R 15345 with an EC 50 of 0.6 µM in MT-4 cells (Table 26 ). Through evaluation of structurally related compounds, R 18893 with a nitro group in place of the methoxy substituent in the ortho position of the aniline moiety was identified as a more potent inhibitor, with an (Pauwels et al., 1993) . At this stage it appeared as the antiviral activity was stereospecific as the (-) isomer was 50-fold more potent (EC 50 33 nM) compared with the (+) isomer (EC 50 1700 nM). Further optimization was made by replacing the nitro substituent with an acetyl group, R88703 and by adding a methyl substituent in the para position of the acetyl group on the aniline moiety. This led to the most potent inhibitor of this series, 90385, with a selectivity index of 80000 (Pauwels et al., 1993) . The compound R 89439 (SI 54,615) was further evaluated against some mutant strains of HIV-RT and RT mutants containing a Y181C or Y188C mutation showed resistance to α-APA derivatives, whereas RT containing a I100L mutation was still sensitive to R 89439. A relatively easy chemical synthesis of R 89439, good oral availability and favourable pharmacokinetics made R 89439 (loviride) a valid candidate (Pauwels et al. 1993) . The α-APA project and further development of loviride has been stopped by Janssen Pharmaceuticals.
Other compounds
A lot of compounds and classes of compounds have been found to have activity against HIV-1 RT have been synthesized. Some of these are presented in Figures 18 and 19 . Compound 1 was the most active of the 5-H-pyrrolo [1,2-b] [1,2,5]benzothiadiazepines (PBTDs) with an EC 50 value of 0.5 M and a selectivity index of >600 . Compound 2, a pyrrolobenzoxazepinone with an IC 50 value in an enzymatic assay (rC.dG) of 250 nM compared to nevirapine (IC 50 500 nM), was the most potent NNRTI in a series by Campiani et al. (1996) . Further work with sulphones and NPPS as a lead afforded the pyrryl aryl sulphones (PAS). Two of these compounds, 3 and 4, had similar anti-HIV-1 activities with an EC 50 of 0.14 µM in MT-4 cells and a selectivity index of >2140. This is a higher EC 50 value and selectivity index than for zidovudine (Silvestri et al., 1997) . With TBZ (5) (Chimirri et al., 1997) as the lead structure, a 2-aryl-substituted benzimidazole 6 with an EC 50 value of 0.20 Μ in an antiviral assay was synthesized (Roth et al., 1997) .
A sulphone compound (7) was found to inhibit viral spread in MT-4 cells with a ClC 95 of 3 nM .
Derivatives of TSAO-T (8) are also inhibitors of HIV-1 RT and are unique in that they interfere at the interface between the p51 and p66 subunits of RT. One 1,2,3-triazole-TSAO analogue, compound 9, is reported to have a selectivity index of 1470 in MT-4 cells (Velázquez et al., 1998) .
Quinoxaline derivatives have also been an important class of NNRTIs. S-2720 has shown activity in a cell spread assay with a 50% effective concentration in the nanomolar range and a selectivity index of 10 4 (Kleim et al., 1993) . HBY 097, another quinoxaline, was withdrawn after finishing Phase IIa clinical testing. HBY 097 showed activity against HIV-1 in PBL (mean of 41 clinical isolates) with an EC 50 of 0.002 µM and with a selectivity index of 12500 (Kleim et al., 1995) . Strains of HIV-1 generated under high selective pressure of HBY 097 revealed a G190E mutation which is characteristic for the quinoxalines (Kleim et al., 1995) . RT with glutamic acid in position 190 has shown a dramatic decrease in enzymatic activity compared to the HIV-1 MN RT (wild-type) (Kleim et al., 1993) . Compound 12 [(R)-9b-(1-naphtyl)-2,3-dihydrothiazolo[2,3-a]isoindol-5(9bH)-one] is a member of the thiazoloisoindol-5-ones, which has shown an EC 50 value of 0.046 µM in MT-2 cells, but the compound was only moderately orally available in rats (Mertens et al., 1993) . Also, the quinoline U-78036 (13) has shown activity against HIV-1 RT (Althaus et al., 1993) . A tetrahydronaphtalene lignan derivative (14) has shown a 50% effective inhibition concentration in antiviral assays of 0.15 to 0.8 µM and a selectivity index of 70-400 (Hiroto et al., 1997) .
Future perspectives for NNRTIs
NNRTIs appear to be very promising therapies in the treatment of HIV, when used in combination with other anti-HIV drugs such as nucleoside RT inhibitors and protease inhibitors. NNRTIs have the advantage that they are able to cross the blood-brain barrier and in this way can have an antiviral effect against HIV-1 infections in reservoirs that are out of reach for many other anti-HIV drugs, including most of the nucleoside RT inhibitors.
The first generation of NNRTIs, nevirapine and delavirdine, have suffered from a rapid development of resistance. To overcome this problem, the NNRTIs have been used in high doses and in combination with two or three other anti-HIV drugs in HAART. The problem of resistant strains of HIV may be reduced with the second generation of NNRTIs because RT will need two or more mutations for HIV-1 to be resistant to these drugs. Also, the uptake of the second generation of NNRTIs in the blood and cells may be increased and thereby increase the concentration that can effect the inhibition of RT. The perspectives of the new generation of NNRTI inhibitors are thus promising with an expected slower development of resistance combined with their ability to cross the blood-brain barrier.
